ResMed: Philips' permanent exit handed the #1 sleep player a decade of share gains priced at 32x earnings

Stevie AI on ResMed Inc. (RMD-USA | resmedincrmd)

4/17/2026

Summary

ResMed is the dominant global provider of CPAP, APAP, and bilevel devices for sleep apnea, with a #1 market position across 140 countries and a deeply integrated digital health ecosystem spanning 11 million myAir cloud users and the AirView provider portal. The structural thesis rests on two compounding forces: first, Philips' irreversible exit from the sleep apnea device market following its 2021 recall has permanently transferred shelf space, prescriber relationships, and resupply contracts to ResMed at a scale that organic competition cannot quickly replicate; second, GLP-1 drug adoption is paradoxically expanding — not shrinking — the addressable patient funnel, as pharmaceutical-driven awareness converts previously undiagnosed patients into active CPAP users at a rate that more than offsets any modest treatment dropout among existing users. The market has oscillated between pricing ResMed as a GLP-1 casualty and pricing it as a cyclical recovery, missing the more durable reality: this is a recurring-revenue consumables business with 59–61% gross margins, rising toward 62–63% by FY2026 per management guidance, and FCF conversion above 90% of net income. ResMed reported FY2024 revenue of $4.7 billion and net income of $1.0 billion, with EPS of $6.92. The step-change from FY2023's $1.5 billion revenue largely reflects full consolidation of the software segment and the continued absorption of Philips' displaced customer base into ResMed's device and mask resupply channels. The mask and accessories segment is the highest-margin, most defensible revenue stream, and its 16% U.S. growth rate in the most recent period signals that share gains are accelerating rather than normalizing. Operating leverage is beginning to surface: SG&A is tracking toward 19–20% of revenue and R&D toward 6–7%, consistent with management guidance, while gross margins are expanding through manufacturing cost improvements, favorable product mix toward consumables, and supply chain normalization. Applying a 32x forward P/E multiple to our FY2026 EPS estimate of $8.50 yields a 12-month price target of $272, representing approximately 21% upside from the current price of $224.72. We view 32x as appropriate for a business growing EPS at 15–17% annually through FY2028, generating over $1.6 billion in FCF by FY2026, transitioning to a net cash position, and operating with near-monopoly positioning in a structurally underpenetrated addressable market where fewer than 20% of diagnosed sleep apnea patients globally are currently treated. On a four-year view, FY2028 EPS of $10.76 at the same multiple implies $344, a 53% total return from current levels. The multiple is not heroic — it is a modest discount to high-quality medical device peers growing at comparable rates.

Thesis

**1. Philips' Recall Is a Structural, Not Cyclical, Share Transfer** The 2021 Philips Respironics recall was not a temporary supply disruption — it was a permanent reputational and operational collapse of ResMed's only scaled global competitor in sleep apnea devices. Philips has since announced its intention to exit the sleep apnea device market entirely, transferring approximately 30–40% of global market share to be absorbed over a multi-year period. ResMed has been the primary beneficiary, reporting 11% global device growth and 16% U.S. mask growth in the most recent period, well in excess of the mid-single-digit underlying market growth rate. Critically, once a patient is initiated on a CPAP device and enrolled in a digital platform like myAir, switching costs are substantial: resupply is automated, compliance data flows to providers through AirView, and mask replenishment occurs on a recurring subscription-like cadence. The patients ResMed has captured from Philips are not returning — Philips has no product to return to. This dynamic means ResMed's market share gains are largely permanent, and the revenue attached to each newly acquired patient is recurring and high-margin. The financial evidence is already visible: mask and accessories revenue, the highest-margin segment, is growing at a double-digit rate well into FY2024 and FY2025, with no deceleration evident in recent quarters. New product launches including the F30i fabric mask and next-generation AirSense platform devices are reinforcing this advantage by giving prescribers and DME providers a product refresh cycle that sustains clinical switching costs and extends the competitive gap further. Regulatory approvals for international rollout of these products represent a near-term catalyst for continued share capture outside the U.S. **2. GLP-1 Awareness Is a Net Positive for the Sleep Apnea Addressable Market** The bear case on ResMed centers on GLP-1 drugs such as semaglutide reducing obesity-related sleep apnea and displacing CPAP demand. This view misreads the market dynamics. Sleep apnea is estimated to affect over one billion people globally, with diagnosis rates below 20% in most markets. The primary constraint on ResMed's addressable market is not treatment capacity — it is diagnosis. GLP-1 drug uptake, combined with the associated media coverage of sleep apnea as a comorbidity of obesity, is driving a significant increase in primary care physician (PCP) referrals for sleep studies and home sleep testing. ResMed's own data and public health research confirm that a meaningful subset of patients who lose weight through GLP-1 therapy still require CPAP treatment due to anatomical rather than purely obesity-driven airway obstruction. More importantly, the incremental patient cohort being funneled into sleep testing as a result of GLP-1 awareness is net additive — these are individuals who would never have been diagnosed or treated absent the cultural spotlight on sleep-weight comorbidities. ResMed is actively investing in PCP education programs and wearable device integration specifically to capture this expanding funnel. The net effect is that GLP-1 drugs are functioning as a marketing channel for sleep apnea treatment rather than a substitute. Our forecast assumes mid-single-digit to low-double-digit device volume growth through FY2028 that incorporates this dynamic, without ascribing speculative upside to GLP-1 conversion rates that remain uncertain. The risk is asymmetric: if GLP-1-driven diagnosis acceleration exceeds expectations, ResMed's device volumes materially outperform; if the effect is neutral, the core compounding business model remains intact. **3. Gross Margin Expansion Is Underwritten by Management Guidance and Structural Mix Shift** ResMed's gross margin trajectory is one of the most compelling financial stories in the medical device sector. Management has guided to 62–63% non-GAAP gross margins for full FY2026 and has publicly committed to 310+ basis points of annual gross margin improvement through 2030 at a recent healthcare conference. Our forecasts of 59–61% for FY2025–FY2026 are actually conservative relative to this guidance, suggesting potential upside to our operating income estimates if the mix shift toward masks and accessories accelerates faster than modeled. The three drivers of margin expansion are well-understood and self-reinforcing. First, manufacturing cost improvements and supply chain normalization following the COVID-era component shortage cycle are reducing device cost of goods. Second, product mix is shifting toward higher-margin masks and accessories, which carry superior gross margins relative to hardware devices and grow on a recurring resupply cadence. Third, operating leverage on a largely fixed SG&A and R&D cost base is becoming visible as revenue scales toward $5–7 billion: SG&A is contracting as a percentage of revenue toward 19–20% and R&D toward 6–7%, consistent with management targets. By FY2028, we forecast net income of $2.0 billion on $6.8 billion of revenue, implying operating margins in the 28–30% range and FCF of $1.9 billion. This FCF generation will fund continued debt reduction — moving from $0.3 billion net cash in FY2025 to $3.3 billion net cash by FY2028 — as well as a growing dividend and $300–400 million of annual buybacks. The balance sheet transition from net debt to substantial net cash is a significant, underappreciated re-rating catalyst: it reduces financial risk, increases capital return capacity, and signals management confidence in the durability of the earnings stream. **4. The Digital Health Ecosystem Creates Barriers That Pure Device Competitors Cannot Replicate** ResMed's competitive position is often described in terms of device market share, but the more durable advantage lies in its data and software infrastructure. The myAir platform serves 11 million active users generating continuous compliance, therapy efficacy, and adherence data. The AirView provider portal integrates this data into clinical workflows for prescribers, DME providers, and payers. This creates a three-sided network effect: patients benefit from personalized therapy coaching, providers benefit from automated compliance reporting that satisfies CMS reimbursement requirements, and ResMed benefits from the switching costs embedded in provider workflow integration. The Residential Care Software (RCS) segment — which includes practice management and clinical workflow software for home health and senior living providers — adds a second dimension to this digital positioning. While RCS is a smaller contributor to group revenue, it provides enterprise-level relationships with large provider networks that serve as distribution channels for device and mask resupply. Mid-single-digit growth in this segment is forecast to continue, providing stable recurring software revenue that diversifies the revenue base and supports the overall gross margin profile. No new entrant can replicate this ecosystem quickly. Building the cloud infrastructure, achieving CMS compliance certification, establishing provider portal integrations, and accumulating the clinical data required to power AI-driven adherence coaching takes years and hundreds of millions of dollars. Fisher & Paykel, the nearest device competitor, lacks comparable software depth. The digital layer is therefore not an incremental feature — it is the primary reason ResMed's market share gains are sticky rather than transactional. **5. Valuation Is Undemanding Relative to the Earnings Growth Path** At $224.72, ResMed trades at approximately 32x trailing EPS of $6.92 and 32x our FY2025 EPS estimate of $6.92. On FY2026 consensus EPS of $8.50, the stock trades at approximately 26x, falling further to 23x on FY2027 EPS of $9.61 and 21x on FY2028 EPS of $10.76. This is an unusually attractive PEG profile for a business with 15–17% annual EPS growth, 90%+ FCF conversion, a net cash balance sheet by FY2026, and #1 global market positioning in a structurally underpenetrated market. Comparable medical device companies with similar growth profiles — including Insulet, Inspire Medical, and Penumbra — trade at 35–55x forward earnings. ResMed's discount to this peer group reflects residual GLP-1 overhang anxiety and the market's tendency to underweight the Philips structural windfall as a one-time event rather than a multi-year compounding dynamic. As GLP-1 patient data accumulates and confirms net-positive diagnosis trends, and as Philips' absence from the market becomes a permanent structural feature rather than a near-term disruption, we expect the valuation discount to compress toward 30–35x forward earnings. Applying a consistent 32x multiple to our four-year EPS path generates price targets of $221 (FY2025), $272 (FY2026), $308 (FY2027), and $344 (FY2028). The FY2026 target of $272 represents 21% upside from current levels within 12 months, with the four-year return of approximately 53% not requiring any multiple expansion — it is driven entirely by earnings compounding. If the multiple re-rates to 35x as GLP-1 fears dissipate, FY2026 and FY2027 price targets would be $298 and $336 respectively, implying 33–50% upside on a 12–24 month view.

Risks

**1. GLP-1 Drug Efficacy Exceeds Expectations in Resolving Sleep Apnea** The most structurally significant risk to the thesis is that semaglutide and tirzepatide prove more effective at resolving sleep apnea than current clinical data suggests. The SURMOUNT-OSA trial demonstrated meaningful AHI reductions in obese sleep apnea patients on tirzepatide, and if long-term real-world data confirms durable resolution rates above 30–40% in the treated population, the net diagnosis tailwind may be more than offset by treatment discontinuation among existing device users. ResMed's installed base of approximately 15–20 million active device users represents a meaningful revenue risk if resupply attrition accelerates beyond model assumptions. We have not ascribed significant risk to this scenario in our base case, but it represents a genuine tail risk that could reduce our FY2027–FY2028 revenue estimates by 5–10% if GLP-1 adoption scales faster than anticipated. **2. Tariff and Regulatory Environment Uncertainty** ResMed's CPAP and bilevel products currently benefit from Nairobi Protocol tariff relief and have been excluded from CMS competitive bidding for the first time in 15 years — both meaningful tailwinds for cost structure and reimbursement stability. However, ongoing Section 232 tariff investigations and the broader uncertainty around U.S. trade policy create real risk to this favorable positioning. If Nairobi Protocol relief is curtailed or if new tariffs are applied to sleep therapy devices, cost of goods could increase by 2–5 percentage points, partially offsetting the gross margin expansion trajectory that underpins much of our operating income forecast. Management has not fully quantified the tariff exposure on a worst-case basis, and this remains an unresolved uncertainty heading into FY2026. **3. Competitive Re-entry or New Market Entrant** While Philips' exit appears permanent, the sleep apnea device market's attractive margin profile could attract well-capitalized entrants over a 3–5 year horizon. Large medical device conglomerates such as Medtronic or Abbott could theoretically acquire Fisher & Paykel or a software-enabled sleep diagnostics company to build a competitive platform. More immediately, Fisher & Paykel continues to invest in device and mask innovation and holds a credible #2 position in several international markets. Any meaningful acceleration in Fisher & Paykel's U.S. market share gains, or a transformative acquisition by a larger strategic player, could disrupt the benign competitive environment that supports ResMed's current pricing power and margin profile. **4. Software Segment (RCS) Growth Deceleration or Competitive Pressure** The Residential Care Software segment faces competitive pressure from dedicated health IT vendors and large EHR platforms such as Epic and Oracle Health, which are expanding into home health workflow management. RCS growth has been mid-single-digit, and any acceleration in competitive displacement within this segment would reduce a relatively stable and high-margin recurring revenue stream. More broadly, the RCS segment's strategic value as a distribution channel for device and mask resupply depends on the continued fragmentation of the home health provider market — consolidation among large DME and home health operators could give them sufficient bargaining power to reduce RCS switching costs and renegotiate commercial terms. **5. Manufacturing Concentration and Supply Chain Disruption** ResMed's manufacturing is primarily concentrated in Singapore and Sydney, with meaningful exposure to Asia-Pacific supply chain risks including component availability, currency movements (AUD/SGD versus USD), and geopolitical disruption. While the company has made progress in supply chain diversification following the COVID-era chip shortage, a recurrence of component scarcity — particularly for the semiconductor chips embedded in AirSense devices — could constrain device availability during a period of strong demand, as occurred in FY2022. The new Greenwood, Indiana distribution center will improve U.S. last-mile logistics but does not address upstream manufacturing concentration risk. **6. FY2025 EPS Flat Year Creates Near-Term Sentiment Risk** Our forecast shows FY2025 EPS of $6.92, flat with FY2024's reported $6.92. This reflects investment spending, the timing of gross margin improvement, and the absorption of tariff and cost headwinds in the near term before operating leverage fully materializes in FY2026. If investors focus on the flat EPS year in isolation — particularly in a market environment that penalizes any earnings deceleration in premium-multiple healthcare names — there is a risk of near-term multiple compression toward 28–30x, which would imply a stock price closer to $194–$208 before the FY2026 earnings acceleration becomes visible. Investors entering at current prices should have a minimum 12–18 month time horizon to capture the FY2026 earnings inflection.

📈 Price Targets